- NATIONAL HELPLINE: 0800 012 322
- WHATSAPP NUMBER: 0600 123 456
- info@health.gov.za
In the medicine value chain, contract management follows the award of a contract. Contract Management Unit (CMU) is responsible to ensure that all parties including the demanders and suppliers fully understand their obligations and responsibilities as stated on the General Conditions of Contract (GCC) and Special Requirements and Conditions of Contract (SRCC).
There are many factors that challenge supply chain processes and ultimately affect medicine availability and accessibility. These supply challenges prompt CMU to embark on interventions to manage stock outs in the short-term, some of these interventions are listed below:
| If you are aware of items that are in short supply but which are not on the list, please notify the Department using the following e-mail address: stockalert@health.gov.za. Stock-out Escalation Protocol February 2024 |
The management of the bulk procured Section 21 medicines in the public sector is undertaken by the Affordable Medicines Directorate at National Department of Health (NDoH). Section 21 medicines are unregistered medicines in South Africa and these medicines are sourced through SAHPRA. NDoH applies for bulk Section 21 authorisations from SAHPRA. SAHPRA may provide authority for the bulk sale and use of the unregistered medicine in accordance with the provisions of the Medicines and Related Substances Act 101 of 1965. The use of the unregistered medicine is considered only for emergency situations where the registered essential medicine is not available for an unmet medical need and there is no therapeutic alternative. Section 21 medicines should only be limited to essential medicines.
Hot List means a list of all essential medicines on contract with stock availability of below 90% and with total orders exceeding supplier stock on hand and total provincial stock on hand less than two months of forecasted demand. The list includes the root cause for the supply challenge and proposed remedial actions for each listed item.
A formal and structured communication and escalation process was implemented and Improved Medicine and Availability Team (IMAT) was established. The IMAT which comprises of national representatives and provincial representatives meets monthly to discuss the Hot List and other stock availability challenges. This is to ensure consistent and aligned visibility, transparency, communication and focuses on supply challenges that may arise; it will also create a platform for various stakeholders to support each other.
The Hot List is published monthly.
| Hotlist Summary February 2024 |
